ES2194536T3 - Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos. - Google Patents

Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.

Info

Publication number
ES2194536T3
ES2194536T3 ES99960277T ES99960277T ES2194536T3 ES 2194536 T3 ES2194536 T3 ES 2194536T3 ES 99960277 T ES99960277 T ES 99960277T ES 99960277 T ES99960277 T ES 99960277T ES 2194536 T3 ES2194536 T3 ES 2194536T3
Authority
ES
Spain
Prior art keywords
duloxetine
combination
inflammatory drugs
steroid anti
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99960277T
Other languages
English (en)
Inventor
Smriti Iyengar
Carrie Kimberly Jones
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2194536T3 publication Critical patent/ES2194536T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processing Of Meat And Fish (AREA)

Abstract

El uso de duloxetina o una sal o solvato de la misma farmacéuticamente aceptable en combinación con uno o más NSAID para la fabricación de un medicamento para tratar el dolor.
ES99960277T 1998-11-13 1999-11-10 Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos. Expired - Lifetime ES2194536T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10837098P 1998-11-13 1998-11-13

Publications (1)

Publication Number Publication Date
ES2194536T3 true ES2194536T3 (es) 2003-11-16

Family

ID=22321828

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99960277T Expired - Lifetime ES2194536T3 (es) 1998-11-13 1999-11-10 Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.

Country Status (9)

Country Link
US (1) US6245802B1 (es)
EP (1) EP1135121B1 (es)
JP (1) JP2002529499A (es)
AT (1) ATE234090T1 (es)
AU (1) AU1718400A (es)
CA (1) CA2350531A1 (es)
DE (1) DE69905938T2 (es)
ES (1) ES2194536T3 (es)
WO (1) WO2000028980A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
ATE311358T1 (de) * 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
US6528076B2 (en) 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
AU2003229408A1 (en) 2002-06-10 2003-12-22 Philippe Kriwin Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
US20100189797A1 (en) * 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2332176T3 (es) * 2003-10-29 2010-01-28 Philippe Kriwin Formulacion antidepresiva oral que contiene un acido acetilsalicilico para acelerar su accion.
WO2005051378A1 (en) * 2003-11-21 2005-06-09 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
ES2627917T3 (es) 2004-06-28 2017-08-01 The University Of Western Australia Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US20070116643A1 (en) * 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US20070155820A1 (en) * 2005-11-23 2007-07-05 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
MX2010006608A (es) * 2007-12-21 2010-10-05 Paz Arzneimittelentwicklung Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
EP3133160B1 (en) 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
HUE040445T2 (hu) 2009-11-12 2019-03-28 Univ Western Australia Antiszensz molekulák és eljárások betegségek kezelésére
EP2332930A1 (en) * 2009-11-23 2011-06-15 Laboratorios Del. Dr. Esteve, S.A. Salts of duloxetine and NSAIDs for the treatment of pain
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
EP2683394B1 (en) 2011-03-09 2021-01-06 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
RU2506077C1 (ru) * 2013-01-25 2014-02-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинация для профилактики, коррекции и терапии боли, связанной с нейродегенерацией или ассоциированной с соматоформными расстройствами
US9217148B2 (en) 2013-03-14 2015-12-22 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
HK1220154A1 (zh) 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
EA201990684A1 (ru) 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
CN117715632A (zh) 2021-03-09 2024-03-15 恩赛斯生物科学股份有限公司 包含酶可裂解的前药和萘莫司他的组合物及其使用方法
KR20230174213A (ko) 2021-03-09 2023-12-27 엔사이스 바이오사이언시즈 인크. 나파모스타트의 변형된 방출 조성물 및 그의 사용 방법
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.
CN114404409A (zh) * 2022-02-23 2022-04-29 江苏海洋大学 一种可治疗疼痛的药物组合及其应用
US20250186455A1 (en) * 2023-12-07 2025-06-12 Taghogho Agarin Treatment composition for treating chronic pain and mixed pain sites

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250042A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
WO1998046601A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
EP1007041A4 (en) * 1997-04-11 2001-03-07 Lilly Co Eli COMPOSITION FOR TREATING PAIN
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain

Also Published As

Publication number Publication date
WO2000028980A3 (en) 2000-07-27
ATE234090T1 (de) 2003-03-15
DE69905938T2 (de) 2003-11-13
US6245802B1 (en) 2001-06-12
WO2000028980A2 (en) 2000-05-25
CA2350531A1 (en) 2000-05-25
EP1135121B1 (en) 2003-03-12
DE69905938D1 (de) 2003-04-17
JP2002529499A (ja) 2002-09-10
EP1135121A2 (en) 2001-09-26
AU1718400A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
HUP0004532A2 (en) Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
TR200001982T2 (tr) Farmasötik vurulu salınımlı oral dozaj şekli.
DE60041761D1 (de) Tribonektine
NO20006630L (no) Farmasöytisk sammensetning for behandlingen av diabetes
NO970067D0 (no) Nytt farmasöytisk preparat for smertebehandling
DE69939864D1 (de) Ppar-gamma modulatoren
DE69935720D1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
LV12624B (lv) Tienilazolilalkosietanamini to iegusanas panemiens un pielietojums medikamentu legusana
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
ES2173858T3 (es) Analogos de huperzina a.
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
NO20005548D0 (no) Mykobakterieinhibitorer
ATE270551T1 (de) Kombinationspräparat aus 2-methylthiazolidin-2,4- dicarbonsäure und paracetamol
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
TR199801798T2 (xx) Otizm tedavisi.
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
ATE252903T1 (de) Arzneimittel zur behandlung konvulsivischer zustände
BR0112460A (pt) Método para tratamento de sépsis